Introduction
Anti-cancer gene therapy using the thymidine kinase (tk) gene from the herpes simplex virus has been successfully used in experimental models of carcinogenesis 1,2 and more recently in clinical trials. 3 The tk gene product converts a nontoxic nucleoside analogue, ganciclovir (GCV), into a toxic phosphorylated form which inhibits the elongation of DNA strands during cell replication, leading to cell death. 4, 5 An interesting aspect of this approach, from a therapeutic point of view, is that the GCV treatment eliminates not only the tumor cells which incorporate the tk gene (tk + cells) by transduction and express it, but also neighboring tk − tumor cells. Such propagation of toxicity from tk + cells to tk − cells is called a 'bystander effect'. 6 Several hypotheses have been formulated to explain this phenomenon. For example, diffusion of apoptotic vesicles from tk + cells to tk − cells 7 and an increased immune response 8, 9 have been considered. Transfer of toxic phosphorylated nucleotides between tumor cells through gap junctions was shown long ago 10 and has been proposed as the basis for a new form of cancer therapy. 11, 12 In our laboratory, we have demonstrated the transfer of toxic agents from one cell to another via gap junctional intercellular communication (GJIC), leading to the selective killing of tumorigenic cells
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Received 10 February 1998; accepted 8 May 1998 in vitro. 13 Recently, such a phenomenon has been observed by our laboratory and others, confirming that the bystander effect involved in the tk/GCV strategy can be mediated and enhanced in vitro by gap junctions. [14] [15] [16] [17] In poorly communicating cells such as HeLa cells, the tk bystander effect is quite limited. However, after transfection of a gap junction protein gene, connexin 43 (Cx43), HeLa cells became GJIC-competent (Cx43 + ). As a result, even when only 10% of the cells were tk + , GCV led to the elimination of all coexisting tk − cells. 17 Mediation of the bystander effect seems to be a property of connexins in general, since we obtained similar results with another member of the connexin gene family, Cx26. 18 Cx37 has also been observed to induce a bystander effect in a mouse neuroblastoma cell line. 19 So far, it has been shown in a few studies that GJIC, as a mediator of the bystander effect, can compensate for a low number of tk + cells in a tumor, leading to significant inhibition of tumor growth in vivo. 19, 20 These studies, however, examined the effect of GCV only over a short period. In order to see if the bystander effect mediated by GJIC can be maintained in vivo for long periods, after the end of GCV treatment, we have examined tumor formation by mixtures of tk + and tk − HeLa cells with or without a transfected Cx43 gene. 17 Cx43, transfected into these highly human tumorigenic cells, induces GJIC without down-regulating their growth significantly, 21 in contrast to other cell types such as glioma cells. 22 We used nude mice in order to eliminate any possible immune effect. We observed a long-term bystander effect due to Cx43 expression if GCV was administrered either before or after the tumor appeared. Even when only 10% of the cells were Cx43 + -tk + , the size of the tumors was greatly reduced compared with controls for at least 3 weeks after the end of the GCV treatment. These results support the possibility of enhancing GJIC in order to increase the bystander effect which is observed in some antitumor gene therapies. (Figures 1h and  2h ). When some of these tumors were cultured and exposed to GCV (20 m), they were efficiently killed (data not shown), suggesting that Cx43 + -tk + cells formed small tumors not due to their reversion to tk − cells, but possibly due to insufficiently long exposure to GCV. This may reflect what was observed in vitro as a protective effect of cell-to-cell communication against GCV and described as the 'good Samaritan effect'. 23 In vivo bystander effect In order to examine in vivo the bystander effect of the Cx43 gene, Cx43 . This suggests that the bystander effect is not perfect, allowing some tk − cells to avoid the GCV toxicity and form tumors after a long latency period in a few animals (Figure 1f and g ).
Results

Tumorigenicity of Cx43
While the results from the above experiments indicate that the Cx43 gene can mediate the bystander effect efficiently, in order to see whether such an effect occurs in real situations of gene therapy, we treated palpable tumors with GCV. As shown in Figure 2 , a drastic difference was observed between tumors from Cx43 + and Cx43 − cells, even when GCV was given after the tumors appeared. The growth of tumors formed by the Cx43 (Figure 3 ). This may be due to a residual GJIC capacity in Cx43 − cells, as has been previously observed. 24 RT-PCR analyses did not reveal any HSVtk mRNA in any of the tumors we tested, suggesting that the GCV treatment was efficient even if the bystander effect was not complete (Figure 4 ). When these tumors were cultured and exposed to GCV, they were not killed, confirming the lack of HSVtk gene. Moreover, the incompleteness of the bystander effect was not due to loss of the Cx43 gene since its transcript was detected in all the tumors we tested that were derived from Cx43 
Discussion
We have demonstrated in this study that when tumorigenic tk − cells are present alongside tk + cells, GCV can prevent tumor formation in nude mice only if these cells express Cx43. Such a bystander effect of tk + cells upon tk − cells was seen even if GCV was applied to tumors already formed by tk + /tk − HeLa cells. Since this effect was not observed, or was weaker, with HeLa cells not expressing Cx43, the gap junctional intercellular communication (GJIC) mediated by Cx43 is likely to be responsible for the transfer of the toxic phosphorylated GCV molecules from tk + to tk − cells. This transfer appears to be efficient, since the production of the toxic nucleotide by tk + cells that comprised only 10% of the injected cells reduced the tumor size significantly. The size reduction was a long-term effect, which was maintained for at least 3 weeks after the end of GCV treatment. This confirms our previous results obtained with these cells in vitro; a culture containing 10% of tk + cells was eliminated if the cells were communicating through gap junctions. 17 While it is likely that the in vivo bystander effect seen in the present study is due to transfer of toxic GCV nucleotides via Cx43-mediated GJIC, we and others have 21 Therefore, it is possible that by the time the tumors appeared, the level of communication was too low at some places within the tumors to mediate an efficient bystander effect. Before tumor appearance, Cx43 high enough to decrease the GJIC capacity of the cells. This would explain why the bystander effect is most efficient when GCV is given before tumor appearance. In practical gene therapy, the tk gene would be introduced relatively uniformly into cells in the tumor to be treated, rather than as tk + clonal islands, so that the bystander effect would probably be more efficient than we found in our experiments.
A direct role of GJIC in the bystander effect in vivo with GCV has also been demonstrated in two other studies involving transfection of connexin genes. In one of these studies, transfection of the Cx37 gene reduced by up to 60% the weight of tumors induced by mouse neuroblastoma cells when 50% of the cells expressed the tk gene.
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Cx43 gene expression in rat C6 glioma cells induced a similar phenomenon in nude mice even when only 5% of the injected cells were tk + . 20 However, the tumorsuppressive role of endogenous Cx43, which is expressed in parental nontransfected C6 glioma cells, may have interfered with the observed bystander effect. 22 Moreover, in these studies, the mice were killed soon after the end of GCV treatment, preventing estimation of the duration of the bystander effect mediated by the connexins in down-regulating or preventing growth of the induced tumors. To our knowledge, our work is the first to demonstrate a long-term connexin-mediated bystander effect in vivo, since when only 10% of the cells injected into nude mice were Cx43 + -tk + cells, the bystander effect following GCV administration was maintained for at least 3 weeks after treatment ceased. A recent report stated that only cell lines able to transfer phosphorylated GCV molecules from cell-to-cell exhibited a long-term bystander effect. 27 However, this study did not clearly demonstrate the involvement of connexins, and is not easily comparable with ours since it was performed on immune-competent mice or by injecting xenogeneic mixtures of cells into nude mice. The number of injected tumorigenic cells was also five to 10 times lower than the number we injected. A further difference from all previous studies is that we carried out our experiments with human tumorigenic cells, rather than rodent tumor cells.
Some tumors developed after the GCV treatment and thus escaped from the bystander effect; none of these expressed HSVtk mRNA, indicating that our protocol eliminated all tk + cells. Cells from these tumors that were seeded back to culture were resistant to GCV treatment in vitro. In contrast, tumors derived from 100% tk + cells still expressed HSVtk despite the GCV treatment, and cells derived from these tumors were sensitive to GCV in vitro. This suggests that doses of GCV administrered may have been insufficient to kill completely 10 6 injected tk + cells, and underlines the importance of conditions of GCV administration. For instance, our preliminary experiments suggest that GCV treatment, after tumor appearance, once a day is less efficient than the same dose administrered twice a day for a shorter period (data not shown). The tumor size is another critical factor, since we did not observe a long-term bystander effect if the GCV treatment was performed when the tumors had reached 400 mm 3 (data not shown) instead of 200 mm 3 as in this study.
Our study was carried out with immune-incompetent animals. It is probable that the bystander effect would have been stronger in immune-competent mice, since immune response has been proposed to be an important component of the bystander effect in vivo. 9 Enhancing the cell-cell communication capacity by treating tumors with agents such as cyclic AMP 28 or retinoids 29 might also increase the connexin-mediated bystander effect. Recently, enhancement of the bystander effect on killing of mouse mesothelioma cells by GCV in vivo by treating mice with retinoic acids was correlated with increased Cx43 expression and GJIC capacity in vitro. 30 It thus appears that induction of GJIC can provide a useful increase in the bystander effect and compensate for the low number of tumor cells that incorporate the HSVtk gene when classical viral vectors are used. Since low communication capacity seems to be a common feature of the cancer cell phenotype, 31 it is crucial to make such cells communicate more in situ either by directly injecting GJIC enhancers or by introducing functional connexin genes into the tumor cells.
Materials and methods
Cells
Both parental HeLa cells (Cx43 − ) and their Cx43-transfected counterparts (Cx43 + ) were a generous gift from Dr K Willecke's laboratory (Institute of Genetics, University of Bonn, Germany). Their phenotype has been previously characterized. 21, 32 These cell lines were transfected with an expression vector, provided by Dr G Tiraby (P Sabatier University, Toulouse, France), carrying the gene coding for the thymidine kinase of the herpes simplex 1 (HSVtk) virus under a CMV promoter, as previously described. 17 All four different phenotypes (Cx43
were cultivated in Dulbecco's minimum essential medium (Gibco, Paisley, UK) and 10% fetal calf serum (Dutscher, Brumath, France). Cell cultures were incubated at 37°C, under a humidified 5% CO 2 atmosphere, and were routinely subcultured by trypsinization with a medium change, twice weekly. The medium was complemented with puromycin (0.5 g/ml; Sigma, St Louis, MO, USA) and/or zeocin (100 g/ml; Cayla, Toulouse, France) for Cx43 and/or HSVtk transfectants, respectively.
In vivo experiments
The tumorigenicity experiments were carried out by injecting subcutaneously, into the back of 5-week-old male nude mice (Iffa-Credo, l'Arbresle, France), 10 6 cells suspended in 100 l of calcium-, magnesium-free phosphate-buffered saline (PBS). The following tk + /tk − ratios of Cx43 + or Cx43 − HeLa cells were injected into the mice: 100, 50, 10 and 0%. Each group receiving the same ratio of tk + /tk − cells was divided into two subgroups of four mice which were treated intraperitoneally with GCV (Syntex, Puteaux, France) either before or after the appearance of tumors. When injected before the tumors were palpable, GCV (2.5 mg per mouse) was inoculated 5 h after the injection of cells, and then once a day for 4 days. In the other subgroup, the same concentration of GCV was administrered twice a day for 5 days starting 11 days after the cell injection, when the tumors were palpable.
The volume of each tumor was measured two to five times a week, depending on tumor development. After the mice were autopsied, some tumors were randomly put back to culture or kept at −70°C for further molecular analysis to study HSVtk and Cx43 mRNA expression.
RNA extraction and RT-PCR analysis
Total RNA was isolated from frozen tumor tissues with Trizol reagent (Gibco), according to a modified singlestep extraction method. 33 RNA was converted into cDNA and the sequences of interest were amplified using the Titan RT-PCR system (Boehringer, Meylan, France). In a total volume of 50 l, 25 pmol of oligonucleotide primers (Genset, Paris, France) were used to amplify a rodent Cx43 sequence of 344 bp (Cx43-1: 5′-TTCAAT GGCTGCTCCTCACC-3′; Cx43-2: 5′-ATCTCCAGGTCA TCAGGCCG-3′) or 368 bp of the HSVtk sequence (tk-1: 5′-GCTGCTTGCAATACGGTGCG-3′; tk-2: 5′-CGCA-GATCGTCGGTATGGA GCC-3′). Reaction mixtures were incubated for 30 min at 60°C for the reverse transcriptase reaction, and for the PCR, at 95°C for 2 min, followed by 35 cycles of 94°C for 30 s, 54°C for 1 min (for Cx43 amplification) or 55°C for 1 min (for tk amplification), and 68°C for 1 min. A final extension was carried out at 68°C for 7 min. The RT-PCR products were analyzed by electrophoresis on 3% agarose gels in Tris-acetate/EDTA (TAE) buffer after staining with ethidium bromide.
GCV treatment of the tumor cells cultured in vitro
Small fragments from tumors were cut with a razor blade and incubated at 37°C in complemented Dulbecco's minimum essential medium. After confluence, the attached cells were trypsinized, counted and seeded in 60-mm dishes. At 50% confluence, the cells were treated twice a week with GCV (20 m) for 2 weeks. The dishes were then fixed and stained with Giemsa to estimate their resistance to the treatment.
